• 1
    NICE National Guideline Research and Development Unit. Dyspepsia: managing dyspepsia in adults in primary care. Published 23 August 2004. Available at: Accessed November 28, 2011.
  • 2
    Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of twelve case-control studies nested within prospective cohorts. Gut 2001; 49: 34753.
  • 3
    PCT Board Prescribing Report (August 2010), Drugs for Dyspepsia – Prescribing Guidance and Discussion Points. Available at: Accessed November 28, 2011.
  • 4
    Malfertheiner P, Megraud F, O'Morain C. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 77281.
  • 5
    Wuppenhorst N, Stueger HP, Kist M, et al. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 64853.
  • 6
    Wüppenhorst N, Lenze F, Ross M, et al. Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother 2011; 66: 2223.
  • 7
    Buzás GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16: 386570.
  • 8
    Toracchio S, Capodicasa S, Soraja DB, et al. Rifabutin based triple therapy for eradication of H. pylori resistant to tinidazole and clarithromycin. Dig liver Dis 2005; 37: 338.
  • 9
    Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicentre study of 300 patients. Am J Gastroenterol 2008; 103: 716.
    Direct Link:
  • 10
    Chisholm SA, Owen RJ. From Nobel to no cure: a case for monitoring antibiotic resistance in the gastric pathogen Helicobacter pylori. Expert Rev Anti Infect Ther 2007; 4: 34951.
  • 11
    Chisholm SA, Teare EL, Davies K, et al. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill 2007; 12: E34.
  • 12
    Health Protection Agency Standards Unit, Standards and Evaluations laboratory. Investigation of gastric biopsies for Helicobacter pylori. National Standard Methods. 2008 BSOP55. Available at: Accessed November 28, 2011.
  • 13
    Megraud F, Mist M, Lopez Brea M, et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008–2009 [abstract Sa1715] Digestive Disease Week 2011. Available at: Accessed November 29, 2011
  • 14
    Glocker E, Bogdan C, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007; 59: 8749.
  • 15
    Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA+Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 3416.
  • 16
    Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16(Suppl. 1): 19.
  • 17
    Sonnenberg A, Lash RH, Genta RM. A national study of Helicobacter pylori infection in gastric biopsy specimens. Gastroenterology 2010; 139: 1894901.
  • 18
    Santos IS, Boccio J, Davidson L, et al. Helicobacter pylori is not associated with anaemia in Latin America: results from Argentina, Brazil, Bolivia, Cuba, Mexico and Venezuela. Public Health Nutr 2009; 12: 186270.
  • 19
    Hirai I, Sasaki T, Kimoto A, et al. Assessment of East Asian-type cagA-positive Helicobacter pylori using stool specimens from asymptomatic healthy Japanese individuals. J Med Microbiol 2009; 58: 114953.
  • 20
    Zhang ND-H, Zhou L-Y, Lin S-R, et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J 2009; 122: 175963.
  • 21
    Gene E., Calvet X., Azagra R., Gisbert J.P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003; 17: 113743.
  • 22
    Dore MP, Leandro G, Realdi G, et al. Effect of pre-treatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 5876.
  • 23
    O'Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22: 11237.
  • 24
    Raymond J, Lamarque D, Kalach N, et al. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010; 15: 217.
  • 25
    Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 3469.
  • 26
    Chang WL, Sheu BS, Cheng HC, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009; 24: 12305.
  • 27
    Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 114956.
  • 28
    Heep M, Beck D, Bayerdoffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 14979.
  • 29
    Nishizawa T, Suzuki H, Matsuzaki J, et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother 2011; 55: 53745.
  • 30
    Health Protection Agency. Management of Infection Guidance for Primary Care. 2011. Available at: Accessed November 28, 2011.
  • 31
    McNulty CAM, Dent JC, Ford GA, et al. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988; 22: 72938.
  • 32
    Kist M, Glocker E. ResiNet – a nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. Eurosurveill 2004; 9: 446.
  • 33
    Vaira D, Gatta l, Ricci C, et al. A comparison amongst three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic. Intern Emerg Med 2010; 5: 417.
  • 34
    Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 8203.
  • 35
    Agudo S, Alarcon T, Urruzuno P, et al. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. Diagn Microbiol Infect Dis 2010; 67: 2139.
  • 36
    Gibson JR, Saunders NA, Burke B, et al. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 1999; 37: 37468.
  • 37
    Chisholm SA, Owen RJ, Teare EL, et al. PCT-based diagnosis of Helicobcter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001; 39: 121720.
  • 38
    Lawson AJ, Elviss NC, Owen RJ. Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales. J Antimicrob Chemother 2005; 56: 2826.
  • 39
    Wang LH, Cheng H, Hu FL, et al. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010; 16: 22727.
  • 40
    Wuppenhorst N, Hobmaier B., Kist M. Evaluation of GenoType HelicoDR for molecular detection of H. pylori and its resistance against clarithromycin and fluoroquinolones. XXIII International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer. Helicobacter 2010; 15: 387.
  • 41
    De Francesco V, Zullo A, Ierardi E, et al. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65: 32732.